全文获取类型
收费全文 | 17929篇 |
免费 | 1136篇 |
国内免费 | 141篇 |
专业分类
耳鼻咽喉 | 121篇 |
儿科学 | 499篇 |
妇产科学 | 376篇 |
基础医学 | 2874篇 |
口腔科学 | 346篇 |
临床医学 | 1473篇 |
内科学 | 4479篇 |
皮肤病学 | 301篇 |
神经病学 | 1792篇 |
特种医学 | 598篇 |
外科学 | 1391篇 |
综合类 | 48篇 |
一般理论 | 5篇 |
预防医学 | 1383篇 |
眼科学 | 206篇 |
药学 | 1328篇 |
中国医学 | 61篇 |
肿瘤学 | 1925篇 |
出版年
2024年 | 18篇 |
2023年 | 176篇 |
2022年 | 311篇 |
2021年 | 663篇 |
2020年 | 396篇 |
2019年 | 540篇 |
2018年 | 583篇 |
2017年 | 485篇 |
2016年 | 547篇 |
2015年 | 596篇 |
2014年 | 754篇 |
2013年 | 999篇 |
2012年 | 1621篇 |
2011年 | 1620篇 |
2010年 | 891篇 |
2009年 | 800篇 |
2008年 | 1308篇 |
2007年 | 1208篇 |
2006年 | 1153篇 |
2005年 | 998篇 |
2004年 | 909篇 |
2003年 | 762篇 |
2002年 | 657篇 |
2001年 | 90篇 |
2000年 | 57篇 |
1999年 | 103篇 |
1998年 | 126篇 |
1997年 | 107篇 |
1996年 | 102篇 |
1995年 | 57篇 |
1994年 | 46篇 |
1993年 | 51篇 |
1992年 | 39篇 |
1991年 | 35篇 |
1990年 | 49篇 |
1989年 | 40篇 |
1988年 | 42篇 |
1987年 | 57篇 |
1986年 | 43篇 |
1985年 | 25篇 |
1984年 | 24篇 |
1983年 | 15篇 |
1982年 | 13篇 |
1981年 | 12篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1977年 | 6篇 |
1973年 | 10篇 |
1971年 | 5篇 |
1966年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. 总被引:1,自引:0,他引:1
Luigino Dal Maso Silvia Franceschi 《Cancer epidemiology, biomarkers & prevention》2006,15(11):2078-2085
The present meta-analysis was conducted to evaluate the strength and the consistency of the association between hepatitis C virus (HCV) infection and non-Hodgkin lymphoma (NHL) and other lymphoid neoplasms. Only studies with >or=100 cases which were also adjusted for sex and age were included. Fifteen case-control studies and three prospective studies contributed to present analysis, nine of which had not been included in previous meta-analyses. We calculated the pooled relative risks (RR) with corresponding 95% confidence intervals (95% CI), as a weighted average of the estimated RRs by random-effect models. The pooled RR of all NHL among HCV-positive individuals was 2.5 (95% CI, 2.1-3.0), but substantial heterogeneity was found between studies and by study design. Pooled RRs were 2.5 (95% CI, 2.1-3.1) in case-control studies and 2.0 (95% CI, 1.8-2.2) in cohort ones. The strongest source of heterogeneity seemed to be the prevalence of HCV among NHL-free study subjects (RR for NHL among HCV-positive individuals 3.0 and 1.9, respectively, for >or=5% and <5% HCV prevalence). RRs were consistently increased for all major B-NHL subtypes, T-NHL, and primary sites of NHL presentation. Thus, previous suggestions that the RRs for HCV differed by NHL subtype were not confirmed in our meta-analysis. Associations weaker than with NHL were found between HCV infection and Hodgkin's lymphoma (RR, 1.5; 95% CI, 1.0-2.1) and multiple myeloma (RR, 1.6; 95% CI, 0.7-3.6), but they were based on much fewer studies than NHL. The etiologic fraction of NHL attributable to HCV varies greatly by country, and may be upward of 10% in areas where HCV prevalence is high. 相似文献
992.
993.
Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. 总被引:2,自引:0,他引:2
Martha Grodzki Guillaume Besson Christine Clavel Annie Arslan Silvia Franceschi Philippe Birembaut Massimo Tommasino Ingeborg Zehbe 《Cancer epidemiology, biomarkers & prevention》2006,15(4):820-822
To test the significance of human papillomavirus (HPV) type 16 and HPV16 E6 variants as risk factors for viral persistence and progression to high-grade lesion, we did a nested case-control study within a cohort study of >15,000 Caucasian French women. Three groups infected with high-risk HPV were compared: (a) women with cleared infection (controls, n = 201), (b) women with persistent infection (cases, n = 87), and (c) women who progressed into high-grade lesion (cases, n = 58). Women with persistent HPV infection and those that progressed into high-grade lesions were likelier to harbor HPV16 than other high-risk HPV types [odds ratio (OR), 2.4; 95% confidence interval (95% CI), 1.3-4.3 and OR, 4.2; 95% CI, 2.2-8.1, respectively]. Notably, especially elevated ORs of persistence (3.0; 95% CI, 1.4-6.7) and progression (6.2; 95% CI, 2.7-14.3) were found among women who harbored the HPV16 350G variant. Thus, HPV type and HPV16 variant seem to be risk factors for viral persistence and progression of infections into high-grade cervical lesions. 相似文献
994.
Effect of montelukast on exhaled NO in asthmatic children exposed to relevant allergens 总被引:3,自引:0,他引:3
Giorgio L. Piacentini Diego G. Peroni Michele Miraglia Del Giudice Alessandro Bodini Silvia Costella Lucia Vicentini Attilio L. Boner 《Pediatric allergy and immunology》2002,13(2):137-139
The level of exhaled nitric oxide (FENO) is increased in house dust mite (HDM)-sensitized asthmatic children after exposure to HDM antigen, and inhaled steroids can prevent this increase. The aim of this study was to evaluate whether montelukast could prevent an increase in FENO levels in allergic asthmatic children after a brief period of exposure to relevant allergens. Sixteen children were evaluated at the residential house 'Istituto Pio XII' (Misurina, Bellunio, Italy) in the Italian Alps, a dust mite-free environment. FENO levels were evaluated before ( t 0 ) and immediately after ( t 1 ) the children were exposed to HDM allergens for 2 weeks in their homes at sea level. No significant difference in FENO was observed in the fluticasone-treated group of children after 2 weeks at sea level. In the group treated with montelukast, an increase in FENO was observed between t 0 and t 1 , which failed to reach statistical significance. These preliminary data suggest that oral montelukast could be effective in preventing the relapse in airway inflammation in allergic asthmatic children who are occasionally exposed to relevant allergens for a short period of time. 相似文献
995.
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. 总被引:1,自引:0,他引:1
Silvia Brugnatelli Marco Danova Manuela Tamburo De Bella Marina Vaglica Giovanna Manuguerra Alberto Riccardi Sergio Palmeri 《Oncology》2002,62(1):33-38
OBJECTIVE: This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). METHODS: Heavily pretreated patients with MBC, aged 18-75 years with World Health Organization performance status of 0-2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m(2)) followed by a weekly fixed dose of gemcitabine, 800 mg/m(2), were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade > 3 hematologic toxicity and grade > 2 stomatitis, asthenia, diarrhea or organ-specific toxicity (except alopecia). Dose escalation was stopped if > or = 3 of 5 patients at any dose level experienced DLT. RESULTS: Eighteen patients (median age 56 years) received a mean of 4.1 (range 1-6) cycles. Asthenia, stomatitis and leukopenia were the main DLTs. One of 5 patients had DLT at dose level 1 and 2 of 5 patients at dose level 2. At dose level 3, 3 of 5 patients had DLTs. Three additional patients treated at dose level 3 confirmed that the MTD had been reached. Therefore, the recommended docetaxel dose in combination with gemcitabine 800 mg/m(2) for phase II studies was established at the next lower dose, 35 mg/m(2). Of 12 evaluable patients, 7 (58%) achieved an objective response. CONCLUSIONS: Gemcitabine 800 mg/m(2) plus docetaxel 35 mg/m(2) on days 1, 8 and 15 of a 28-day cycle is a safe regimen which shows activity in heavily pretreated patients with MBC. Further phase II investigations with this combination are now warranted. 相似文献
996.
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. 总被引:10,自引:0,他引:10
Markus M Borner Daniel Dietrich Roger Stupp Rudolf Morant Hanspeter Honegger Martin Wernli Richard Herrmann Bernhard C Pestalozzi Piercarlo Saletti Silvia Hanselmann Samuel Müller Peter Brauchli Monica Castiglione-Gertsch Aron Goldhirsch Arnaud D Roth 《Journal of clinical oncology》2002,20(7):1759-1766
PURPOSE: To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer. PATIENTS AND METHODS: Forty-three nonpretreated patients and 26 patients who had experienced one fluoropyrimidine-containing regimen for advanced colorectal cancer were treated with oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1,250 mg/m(2) bid on days 1 to 14 every 3 weeks. Patients with good performance status (World Health Organization grade 0 to 1) were accrued onto two nonrandomized parallel arms of a phase II study. RESULTS: The objective response rate was 49% (95% confidence interval [CI], 33% to 65%) for nonpretreated and 15% (95% CI, 4% to 35%) for pretreated patients. The main toxicity of this combination was diarrhea, which occurred at grade 3 or 4 in 35% of the nonpretreated and 50% of the pretreated patients. Grade 3 or 4 sensory neuropathy, including laryngopharyngeal dysesthesia, occurred in 16% of patients on both cohorts. Capecitabine dose reductions were necessary in 26% of the nonpretreated and 45% of the pretreated patients in the second treatment cycle. The median overall survival was 17.1 months and 11.5 months, respectively. CONCLUSION: Combining capecitabine and oxaliplatin yields promising activity in advanced colorectal cancer. The main toxicity is diarrhea, which is manageable with appropriate dose reductions. On the basis of our toxicity experience, we recommend use of capecitabine in combination with oxaliplatin 130 mg/m(2) at an initial dose of 1,250 mg/m(2) bid in nonpretreated patients and at a dose of 1,000 mg/m(2) bid in pretreated patients. 相似文献
997.
Stefan Fr?hling Silvia Skelin Claudia Liebisch Claudia Scholl Richard F Schlenk Hartmut D?hner Konstanze D?hner 《Journal of clinical oncology》2002,20(10):2480-2485
PURPOSE: To prospectively compare cytogenetic and molecular cytogenetic analysis for the detection of the most relevant chromosome abnormalities in a large series of patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: Two hundred forty consecutive adult patients with AML entered onto the multicenter treatment trial AML HD93 were studied. Chromosome banding and fluorescence in situ hybridization (FISH) applying a comprehensive set of genomic DNA probes were performed in a single reference laboratory. RESULTS: Two cases of inv(16), three cases of t(11q23), and three cases of t(8;21)var were only detected by molecular cytogenetics. By FISH, aberrations were identified in three cases with normal karyotypes: inv(16), -Y (in a patient with low metaphase yield on chromosome banding) and a 12p microdeletion. Additional aneuploidies, in particular +8q and +11q, were diagnosed by FISH; however, virtually all these aberrations occurred in patients with complex karyotypes or as an additional abnormality in leukemias with an AML-specific translocation. Finally, aberrations were detected by FISH in eight of 14 patients with no assessable metaphases. CONCLUSION: In most cases of AML, conventional cytogenetic study reliably detects chromosomal abnormalities, and this method should not be replaced by FISH. FISH should be used as a complementary method for the detection of more subtle abnormalities, such as inv(16) and t(11q23), in all patients with newly diagnosed AML and for suspected t(8;21)var. Furthermore, molecular cytogenetics using this comprehensive set of DNA probes provides a valuable diagnostic tool for patients with poor chromosome morphology, low or no yields of metaphase cells, or both. 相似文献
998.
To date, surgery and irradiation remain the standard therapies for anaplastic astrocytoma (AA, WHO grade III) and glioblastoma
multiforme (GBM, WHO grade IV). Due to infiltrative tumor growth a complete surgical resection is never achieved and more
than 90% of the tumors will recur within 2 cm of the primary tumor location. Postoperative radiotherapy prolongs survival
but is not curative and prognosis remains poor with only a few patients being alive 2 years after diagnosis. Over the past
decades multiple trials dealt with the question of whether chemotherapy (CT) may influence the outcome of malignant brain
tumor patients. In general, the results have been disappointing with one exception: chemosensitivity and prolonged survival
after CT have been demonstrated for tumors of oligodendrogial lineage. Drugs showing some activity in malignant brain tumors
and therapeutic concepts will be discussed.
Received: 2 May 2000 / Accepted: 28 May 2000 相似文献
999.
1000.
Objective. This study was designed to compare diagnostic quality of MR images of patients with spinal hardware acquired using a conventional
T1-weighted spin-echo sequence and a new metal artifact reduction sequence (MARS).
Conclusion. The new MARS sequence effectively reduces the degree of tissue-obscuring artifact produced by spinal fixation hardware and
subjectively improves image quality compared with the conventional T1-weighted spin-echo sequence.
Received: 30 May 2000 Revision requested: 12 September 2000 Revision received: 27 September 2000 Accepted: 27 November 2000 相似文献